Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.

Autor: Jaramillo S; Department of Internal Medicine V, Heidelberg University Hospital., Krisam J; Institute of Medical Biometry, University of Heidelberg., Le Cornet L; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center., Kratzmann M; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center., Baumann L; Institute of Medical Biometry, University of Heidelberg., Eissymont O; Institute of Medical Biometry, University of Heidelberg., Crysandt M; Department of Medicine IV, Aachen University Hospital, Aachen., Görner M; Department of Hematology, Oncology and Palliative Medicine, Community Hospital Bielefeld., Kayser S; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Germany; Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University; Department of Medicine I - Hematology and Cell Therapy, University Hospital Leipzig., Krause S; Department of Medicine V, Erlangen University Hospital., Schliemann C; Department of Medicine A, Münster University Hospital., Gaska T; Department of Hematology and Oncology, St. Josef Brothers' Hospital Paderborn., Kaufmann M; Department of Hematology, Oncology and Palliative Medicine, Robert-Bosch Hospital Stuttgart., Chemnitz J; Department of Internal Medicine, Hematology, Oncology and Palliative Medicine, Prot. Monastery Hospital St. Jakob Koblenz., Schaich M; Department of Hematology, Oncology and Palliative Medicine, Winnenden Hospital, Winnenden., Hoellein A; Department of Internal Medicine III - Hematology and Oncology, Red Cross Hospital Munich, Munich., Platzbecker U; Department of Medicine I - Hematology and Cell Therapy, University Hospital Leipzig., Kieser M; Institute of Medical Biometry, University of Heidelberg., Müller-Tidow C; Department of Internal Medicine V, Heidelberg University Hospital., Schlenk RF; Department of Internal Medicine V, Heidelberg University Hospital, Germany; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center.
Jazyk: angličtina
Zdroj: Haematologica [Haematologica] 2024 Jun 01; Vol. 109 (6), pp. 1973-1976. Date of Electronic Publication: 2024 Jun 01.
DOI: 10.3324/haematol.2023.284346
Databáze: MEDLINE